What's in the 42,000+ number
There are 42,000+ health care investors in the AngelMatch database, and the breakdown is more telling than the headline count. About half carry an angel/individual tag, and even more show up under venture capital or private equity investor, since a lot of these people wear more than one hat depending on the deal. Most of them are also early-stage focused: seed and early stage venture tags cover the largest slice of the list, well ahead of anything later, which matters if you're raising a first or second round and wondering whether the bench is deep enough.
What different investors actually bring to a health care deal
Not every health care investor is offering the same thing, even when the check size looks similar on paper. Angel investors here are often domain experts first and financiers second: former clinicians, health system executives, or operators who've built and sold a health care company before. A smaller check from the right angel can open a door to a clinical pilot that a bigger, generic check never would. Venture capital investors bring bigger, more institutional capital, and from Series A onward they'll usually expect a board seat and a real scale story, not just a working product. Private equity investors tend to show up later, and they're more interested in profitability, consolidation, and roll-up plays than in a pre-revenue pitch. If you're raising a seed round, most of your list should skew angel and early-stage venture. Save the private equity conversations for when you have real revenue to show.
Where health care investors are based
The United States dominates this list by a wide margin, home to well over half of all health care investors in AngelMatch. If you're raising in the US, California and New York carry the biggest concentrations, and Massachusetts punches above its weight for a state its size, a reflection of the Boston and Cambridge biotech corridor. Outside the US, the United Kingdom is the next-biggest hub, with London carrying most of that weight. If your startup is based somewhere else entirely, don't skip these lists. Plenty of health care investors write checks well outside their home city, especially once you're past the earliest stage.
Digital health, AI, and where the money's actually going
2025 was a strong year for digital health specifically. US digital health startups raised $14.2 billion in venture funding, up 35% from $10.5 billion in 2024 and the highest total since 2022, according to Rock Health's year-end analysis. Most of that growth went to a small number of very large rounds. AI-enabled companies alone captured 54% of total funding, up from 37% the year before, and the gap between well-funded AI-native startups and everyone else is real. If you're building in digital health without an AI story, expect more scrutiny on your numbers, not less.
Wellness had its own moment too. Wellness-focused startups jumped from the eighth most-funded digital health category in 2024 to third in 2025, and even setting aside a couple of huge outlier rounds, the category still grew by double digits. If you're building in wellness, that's a real tailwind, not just a headline.
Biotech and medtech: a different kind of health care investor
Biotechnology and medical device investors aren't chasing the same growth-at-all-costs story as software or even digital health. They care about clinical data, a credible regulatory path, and a founding team that's navigated FDA processes before. That's slower money to raise, but it's often stickier once you have it, and it tends to come with investors who stay engaged well past the check.
What health care investors want to see before they say yes
Health care investors ask questions other investors don't. Before you send a cold email, be ready to answer three things clearly: what clinical or real-world evidence you have, what your regulatory path looks like even if it's still early, and who's actually going to pay for this once it's built, whether that's a patient, an employer, or a payer. Skipping the reimbursement question is one of the fastest ways to lose a health care investor's attention, even when the product itself works well.
Regulatory pathway matters more here than in almost any other market on this site. A 510(k) clearance, a De Novo pathway, and a full PMA approval are three very different timelines and price tags, and a health care investor will want to know which one applies to you well before term sheet conversations start. You don't need to have cleared anything yet. You do need to know which door you're walking through, since that choice alone can shift your timeline to revenue by years and change which investors are even a fit for you.
How to actually approach them
Lead with outcomes, not features. "Reduces readmissions by 12%" gets read. "AI-powered patient engagement platform" gets skimmed. Put your strongest data point in the first two lines of your email, and keep the rest of the pitch just as tight. Health care investors get pitched constantly, and the ones worth your time can usually tell within a paragraph whether you understand your own market or you're just describing your product. When you're managing outreach to dozens of health care investors at once, it's worth tracking who's opened what and who's actually replied, so you're not guessing which investor to follow up with next.
Check sizes, dilution, and stage fit
The math doesn't change by market. Angel investors in health care, like everywhere else, typically write checks between $25,000 and $500,000. Venture checks run much bigger, from $2 million up to $100 million or more depending on the round. Expect to give up somewhere around 15% to 25% of your company in an early round, which is standard across most industries, health care included.
Budget more time than you would for a typical software raise. Health care deals usually move slower because there's an extra layer of review on top of the normal financial diligence: an investor might want to see clinical outcomes data validated, talk to a couple of your pilot customers directly, or get comfortable with your regulatory timeline before they'll commit. None of that means the deal is dying. It just means the six-week software fundraise timeline isn't a realistic benchmark here, so plan your runway with a longer close in mind.
Where health care differs is the mix of investors you'll actually talk to. Series A health care investors want to see real usage or clinical traction, not just a working prototype, since the regulatory and reimbursement runway is longer here than in most software categories. Before you start pitching, it's worth running your numbers through a valuation calculator so you know roughly what stake you're offering before an investor tells you.
With 42,000+ health care investors in AngelMatch spanning angel investors, venture capital, and private equity, the hard part usually isn't finding names, it's finding the right ones for a company at your clinical stage, your regulatory status, and your data. Start with the filters above to narrow by location, stage, and investor type, then use the AngelMatch investor database to get contact details for the health care investors who actually fit. The list gets you in the door. What you do with the outreach after that is on you.
Early stage venture investors
